About Pi-Cardia
Pi-Cardia is a Healthcare company based in Rehovot (Israel) founded in 2009 by Erez Golan and Eyal Kolka. It operates as a non-implant devices for cardiac valve repair are developed and manufactured. Pi-Cardia has raised $40 million across 4 funding rounds from investors including Clal Biotechnology Industries, Jacques Séguin and Sofinnova Partners. Its chief executive is Erez Golan. Pi-Cardia offers products and services including ShortCut Device and Leaflex Performer. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Shockwave Medical, Venus MedTech, Cardiac Dimensions, Peijia Medical Technologies and MicroPort CardioFlow Medtech Corporation and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Pi-Cardia was established in 2009 in Rehovot, Israel, within the medical device sector focused on cardiology. Non-implant solutions for valve repair are produced, including the Leaflex device. Separation between calcium deposits on valve leaflets is created by its scoring lines, which restores leaflet flexibility, supports mobility, and enhances overall valve hemodynamics. Operations center on advancing treatments for structural heart conditions.
- Headquarters Rehovot, Israel
- Founders Erez Golan, Eyal Kolka
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pi-cardia.net
- Social LinkedIn X
- Total Equity Funding$40M (USD)
in 4 rounds
- InvestorsClal Biotechnology Industries
& 5 more
Products & Services of Pi-Cardia
Pi-Cardia offers a comprehensive portfolio of products and services, including ShortCut Device and Leaflex Performer.
Tool for splitting bioprosthetic valve leaflets to prevent obstruction.
Device for next-generation aortic repair in heart disease.
Funding Insights of Pi-Cardia
Pi-Cardia has successfully raised a total of $40M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 4
- First Round $10M
(Jan 2016)
- Investors Count 6
All 4 funding rounds of Pi-Cardia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | – | Series D | – | – | |
| Apr 2020 | $27M | Series D | – | Sofinnova Partners | |
| Dec 2018 | $3M | Series C | – | Clal Biotechnology Industries | – |
| Jan 2016 | $10M | Series C | – | Innogest Capital, VI Ventures | – |
6 investors in total: 5 institutional and 1 angel.
Investors in Pi-Cardia
Pi-Cardia has secured backing from 6 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Clal Biotechnology Industries, Jacques Séguin and Sofinnova Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Life Sciences focused VC firm investing in Israel and the US | 1993 | cbi.co.il | Tel Aviv, Israel | |
VC firm investing in seed and early stage companies in Italy | – | innogestcapital.com | Milan, Italy | |
- | – | vi-ventures.com | - | |
- | – | medtronic.com | - | |
JS Jacques Séguin | - | – | unknown_0be64e031e1a4a6ca | - |
Investor details for Pi-Cardia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pi-Cardia
34 people are tracked at Pi-Cardia (13 in leadership, 21 in team).
| Name | Role | Group |
|---|---|---|
Erez Golan | Co-Founder & CEO | Leadership |
Eyal Kolka | Co-Founder | Leadership |
Benzi (Ben Zion) Spector | Chief Technology Officer | Leadership |
Hardip Thakerar | Global VP Therapy Development | Leadership |
Merav Gat | VP Clinical Affairs | Leadership |
Ofir Gal-Or | Director Of Product Development | Leadership |
Ronnie Levy | Chief Operating Officer | Leadership |
Yaron Sasson | Vice President Operations | Leadership |
Eric Cheek | Director of Therapy Development U.S. | Leadership |
Tami Sharbit-Bachar | Director of Finance & Controller | Leadership |
Hadas Givon | VP Of RA & CA | Leadership |
Julie Khol | Director Marketing & Education | Leadership |
Gary Gratson | Vice President Of Commercial Operations | Leadership |
Ran Moshe | Engineering Team Lead | Team |
Roy Dar | Principal Scientist | Team |
Liran Shmuel Wischnia | Office Manager & HR Specialist | Team |
Ekaterina Kosachevski | Senior Quality Assurance Specialist | Team |
Christoph Lesser | Therapy Development Manager | Team |
Sahar Benjamin Amsterdam | Research Project Lead | Team |
Marom Mizrachi | Research Development Mechanical Engineer | Team |
14 more people are available in the full profile.
Complete people profiles for Pi-Cardia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pi-Cardia
3 dated milestones of Pi-Cardia across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Pi-Cardia is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series D,.
Competitors of Pi-Cardia
Pi-Cardia has 9 listed competitors in our database, 8 of them funded. They include Shockwave Medical, Venus MedTech, Cardiac Dimensions, Peijia Medical Technologies and MicroPort CardioFlow Medtech Corporation, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| shockwavemedical.com | 2009 | Santa Clara, United States | $147.5M | 1,394 | Cardiovascular balloon dilation catheters with lithotripsy electrodes are developed. | |
| venusmedtech.com | 2009 | Hangzhou, China | $37M | – | Transcatheter aortic and pulmonic valves are developed for cardiovascular procedures. | |
| cardiacdimensions.com | 2001 | Kirkland, United States | $260.8M | 31 | Invasive cardiac implants for heart failure treatment are developed. | |
| peijiamedical.com | 2012 | Suzhou, China | $110.08M | – | Medical devices for cardiac and cerebrovascular treatments are developed. | |
| cardioflowmedtech.com | 2015 | Pudong, China | $132.02M | – | Smart medical devices for heart valve diseases are developed. | |
| tricares.com | 2013 | Aschheim, Germany | $102.84M | – | Minimally invasive tricuspid valve replacement system is developed. | |
| jenavalve.com | 2006 | Irvine, United States | $363.7M | 198 | Pericardial transcatheter aortic valve replacement systems are provided. | |
| capstanmedical.com | 2020 | Santa Cruz, United States | $141.4M | – | Medical devices for structural heart disease treatment are developed. | |
| anteristech.com | 2011 | Brisbane, Australia | – | 27 | Technologies for heart valve development are provided. |
Detailed competitors of Pi-Cardia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as Pi-Cardia (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pi-Cardia
Complete news archive for Pi-Cardia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pi-Cardia
Pi-Cardia was founded in 2009 and raised its 1st funding round 7 years after it was founded.
Pi-Cardia is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
Erez Golan is the current CEO of Pi-Cardia. They have also founded this company.
Pi-Cardia is a funded company, having raised a total of $40M across 4 funding rounds to date. The company's 1st funding round was a Series C of $10M, raised on Jan 2016.
Pi-Cardia was established in 2009 in Rehovot, Israel, within the medical device sector focused on cardiology. Non-implant solutions for valve repair are produced, including the Leaflex device. Separation between calcium deposits on valve leaflets is created by its scoring lines, which restores leaflet flexibility, supports mobility, and enhances overall valve hemodynamics. Operations center on advancing treatments for structural heart conditions.
Pi-Cardia's top competitors include Shockwave Medical, Cardiac Dimensions and JenaValve Technology.
Pi-Cardia offers ShortCut Device and Leaflex Performer.
Pi-Cardia has 6 investors. Key investors include Clal Biotechnology Industries, Jacques Séguin, Sofinnova Partners, Innogest Capital, and VI Ventures.